The biogenesis and biology of amyloid β oligomers in the brain

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The repeated failure of clinical trials targeting the amyloid beta (Aβ) protein has challenged the amyloid cascade hypothesis. In this perspective, I discuss the biogenesis and biology of Aβ, from the arrangement of its atoms to its effects on the human brain. I hope that this analysis will help guide future attempts to home in on this elusive therapeutic target.

Original languageEnglish (US)
Pages (from-to)1561-1567
Number of pages7
JournalAlzheimer's and Dementia
Issue number11
StatePublished - Nov 2020

Bibliographical note

Funding Information:
I thank David Knopman and Rob Tycko for provocative discussions and insightful comments about this manuscript, and Peng Liu for his vital contributions to the delineation and characterization of type 1 and type 2 oligomers in the brain. Funding: NIH R01-NS/AG33249, B. Grossman, T. and P. Grossman Family Foundation.

Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association


Dive into the research topics of 'The biogenesis and biology of amyloid β oligomers in the brain'. Together they form a unique fingerprint.

Cite this